Form 4 for STOK Stoke Therapeutics, Inc.
Accepted 2022-05-26 00:00:00 ET · period of report 2022-05-25 · accession 0001209191-22-032259 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-26 | 2022-05-25 | STOK | Kaye Edward M. MD | CEO, Dir | M - OptEx | $0.6 | +15.0K | 25.0K | +150% | +$9,000 |
| D | 2022-05-26 | 2022-05-25 | STOK | Kaye Edward M. MD | CEO, Dir | M - OptEx | $0.00 | -15.0K | 622.8K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-25 | M | A | 15,000 | $0.6 | 25,000 | D | — | — | |
| 2 | Derivative | Employee Stock Option (right to buy) | 2022-05-25 | M | D | 15,000 | $0.00 | 622,801 | D | $0.6 · — to 2028-04-02 | 15,000 Common Stock | (F1) The option vested as to 1/4th of the total shares on October 17, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. |